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Abstract
Background: Since only little is known on stem cell therapy in non-ischemic heart failure we wanted to know
whether a long-term improvement of cardiac function in non-ischemic heart failure can be achieved by stem cell
transplantation.
Methods: White male New Zealand rabbits were treated with doxorubicine (3 mg/kg/week; 6 weeks) to induce
dilative non-ischemic cardiomyopathy. Thereafter, we obtained autologous bone marrow stem cells (BMSC) and
injected 1.5–2.0 Mio cells in 1 ml medium by infiltrating the myocardium via a left anterolateral thoracotomy in
comparison to sham-operated rabbits. 4 weeks later intracardiac contractility was determined in-vivo using a
Millar catheter. Thereafter, the heart was excised and processed for radioligand binding assays to detect β1- and
β2-adrenoceptor density. In addition, catecholamine plasma levels were determined via HPLC. In a subgroup we
investigated cardiac electrophysiology by use of 256 channel mapping.
Results:  In doxorubicine-treated animals β-adrenoceptor density was significantly down-regulated in left
ventricle and septum, but not in right ventricle, thereby indicating a typical left ventricular heart failure. Sham-
operated rabbits exhibited the same down-regulation. In contrast, BMSC transplantation led to significantly less
β-adrenoceptor down-regulation in septum and left ventricle. Cardiac contractility was significantly decreased in
heart failure and sham-operated rabbits, but was significantly higher in BMSC-transplanted hearts. Norepinephrine
and epinephrine plasma levels were enhanced in heart failure and sham-operated animals, while these were not
different from normal in BMSC-transplanted animals. Electrophysiological mapping revealed unaltered
electrophysiology and did not show signs of arrhythmogeneity.
Conclusion: BMSC transplantation improves sympathoadrenal dysregualtion in non-ischemic heart failure.
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Background
Stem cell transplantation, in particular transplantation of
mesenchymal autologous bone marrow stem cells, is cur-
rently discussed to be a possible alternative to heart trans-
plantation and may be of therapeutic interest in ischemic
heart disease [1-3]. The use of autologous bone marrow
stem cells (BMSC) has the advantage of non-immunoge-
neity. Until now there are a number of experimental [4-6]
and also clinical [7-11] studies demonstrating positive
effects of stem cell therapy in ischemic heart disease. How-
ever, at present there is only little knowledge on the use of
autologous stem cells in non-ischemic cardiomyopathy.
Thus, we decided to investigate the effect of autologous
bone marrow stem cell transplantation in doxorubicine-
induced non-ischemic cardiomyopathy in rabbits using
direct epicardial infiltration for delivery.
A special problem with the evaluation of such a therapy is
to get an impression of the long-term improvement in
hemodynamics and in the sympathoadrenal regulation.
Thus, echocardiography and related methods give a meas-
ure for the acute contractility at the moment of investiga-
tion, but do not allow an insight into the
sympathoadrenal dysregulation typical for heart failure
[12] or its possible normalisation by therapy. The idea of
our study was to assess the effect of BMSC transplantation
therapy on non-ischemic heart failure by measurement of
contractility and β-adrenoceptor density using (-)-125 [I ]-
iodocyanopindolol radioligand binding assay: it is long
known that heart failure leads to compensatory activation
of sympathoadrenal system with enhanced release of cat-
echolamines and to down-regulation of cardiac β1-adren-
oceptors [13,14], which is correlated to the severity of the
disease [15,16], affecting mostly β1-adrenoceptors while
β2-adrenoceptors remained unaltered in most studies [17]
and finally resulting in a decrease in β-adrenoceptor den-
sity. Remaining β-adrenoceptors are desensitized, proba-
bly mostly via G-protein coupled receptor kinases (GRK2
and/or GRK5) [17-22] and to some extent via pathways
involving PKA [23]. The down-regulation of β-adrenocep-
tor number as assessed via radioligand binding studies
mirrors the severity of chronic heart failure [14]. This
holds also true for rabbits suffering from chronic heart
failure [24].
Treatment of chronic heart failure with the β-blocker
metoprolol results in hemodynamic improvement and
up-regulation of β-adrenoceptor density [25,26]. The
process of β-adrenoceptor down-regulation in chronic
heart failure takes days to weeks and the extent of this
reduction in β-adrenoceptor number is directly related to
the severity of heart failure [13,14,27], thus, reflecting the
long-term hemodynamic situation. Inversely, an effective
therapy of heart failure should lead to better contractility
and in consequence a reduction of heart failure-induced
enhancement in catecholamine levels and finally a (par-
tial) normalisation of β-adrenoceptor density. Therefore,
we decided to measure β-adrenoceptor density, contractil-
ity and catecholamine levels in normal rabbits, doxorubi-
cine-induced non-ischemic cardiomyopathy with or
without autologous BMSC transplantation or sham-oper-
ation.
Methods
The study was performed in accordance to the German
laws for animal health and protection declaration and was
approved by the local authorities, Government of Leipzig
(Reg.-Nr.: 24-9168.11-11/03). We used male White New
Zealand rabbits of 1500–2000 g body weight (at begin-
ning of the study) (conventional, normally fed ad libi-
tum) (Charles River, Kisslegg, Germany).
Animal model and investigation of contractility
Heart failure was induced by repeated i.v. injection of dox-
orubicine 3 mg/kg/week over 6 weeks, followed by a 14
days doxorubicine-free interval. Animals that survived 2
weeks after heart failure induction were randomized to
either no treatment, sham operation or BMSC transplan-
tation. After intramuscular anaesthesia with ketamin (50
mg/kg) and xylazine (5 mg/kg), we obtained autologous
mesenchymal bone marrow stem cells from a femur punc-
tion, isolated the mononuclear stem cell fraction, and
after subcultivation for 4 days (see below), the stem cells
were injected directly into the wall of the left ventricle. For
transplantation rabbits were anaestetized (0.8 vol% iso-
fluran, protocol see [28]. Left thoracotomy through the
intercostal space was performed and the left ventricle was
exposed. Either BMSC (1.5 – 2.0 Mio cells in 1 ml) or
medium (1 ml) was injected at 4 positions into the tissue
of the free lateral wall of the left ventricle in a circular
manner with a 1 ml syringe within 2 minutes.
28 days after the operation, animals were subjected to the
final experiment. One hour prior to surgery (anaesthesia
as described above), we collected 2 ml venous blood in
potassium EDTA monovettes (with addition of 1 µM glu-
tathione/ml plasma) from the rabbits after at least 30 min
at rest for determination of plasma catecholamines. After
centrifugation (600 g/10 min/4°C), plasma was removed,
quickly frozen in liquid nitrogen, and stored at -80°C
until further use. We introduced a Millar catheter designed
for rabbits (FMI, Germany) via the femoral artery and reg-
istered pressure-volume loops under the influence of 1.5
µg/kg dopamine, in order to assess the contractile func-
tion. dP/dtmax and dP/dtmin were determined from these
measurements. Subsequently, we excised the heart for
mapping experiments and radioligand binding assay.
After the experiment, tissue was immediately placed in
cardioplegic solution. Left ventricle, septum and right
ventricle were excised and subsequently shock-frozen.Journal of Cardiothoracic Surgery 2006, 1:17 http://www.cardiothoracicsurgery.org/content/1/1/17
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We investigated 4 groups of rabbits: healthy control ani-
mals (n = 10), doxorubicine-induced heart failure (n = 6),
doxorubicine-induced heart failure with sham operation
(n = 8), and doxorubicine-induced heart failure with stem
cell treatment (n = 14). During the investigations and sub-
sequent evaluations the experimentators were blinded.
Stem cell purification and subcultivation
Under sterile conditions we obtained 1.5 – 2 ml bone
marrow in 2 mM EDTA containing phosphate buffered
saline (PBS) from a femur punction. The mixture was ini-
tially centrifuged at 300 g, at room temperature (RT), for
5 min, and the resulting pellet was resuspended in PBS
containing 2 mM EDTA, and separated in a Ficoll (1.073
g/ml) density gradient centrifugation (cell suspension :
ficoll: 1.5: 1.0; 30 min centrifugation at 500 g, RT). The
mononuclear fraction interphase was collected, washed
twice in PBS/EDTA. The final pellet was resuspended in 12
ml Dulbeccos Modefied Eagle Medium (DMEM) cell cul-
ture medium (+ 10% fetal calf serum, 100 U/ml penicil-
lin, 100 µg/ml streptomycine; 37°C, 5% CO2) and seeded
on gelatine-coated petridishes. For the first 24 hours cells
were incubated with additional 10 µM 5-azacytidine.
Cells were cultured for 4 days. Cell culture medium was
changed every 48 h, and non-adherent hematopoetic cells
were discarded. Prior to transplantation cells were
detached with trypsin/EDTA, and incubated with 2.5 µM
Vybrand DiI cell labelling solution (Molecular Probes) for
0.5 h protected from light in the incubator at 37°C fol-
lowed by 3 washing steps in PBS. Finally, the resulting
mesenchymal mononuclear c-kit positive bone marrow
stem cells (tested using a commercial anti-c-kit antibody)
were suspended in DMEM for injection (1.5–2.0 Mio.
cells in 1 ml).
Radioligand binding study
β-adrenoceptors were assessed by (-) [125I]-iodocyanopin-
dolol (ICYP)-binding assay described elsewhere [29].
Briefly, tissue samples from right ventricle, left ventricle
and septum were homogenised in 10 volumes of ice-cold
1 mmol/l KHCO3 with an Ultra Turrax (Janke and Kunkel,
Staufen, Germany), diluted to 20 ml with 1 mmol/l
KHCO3, centrifuged at 500 g for 10 min, passed through
4 layers of cheesecloth, and centrifuged again at 50,000 g
for 20 min. Pellets were washed once by resuspension and
recentrifugation and finally resuspended in incubation
buffer (Tris-HCl 10, NaCl 154, ascorbic acid 0.55 mmol/
l, pH 7.4, 25°C) at a protein concentration of 0.1–0.2 mg/
ml. Protein content was determined by the method of
Lowry using bovine serum albumine as a standard.
The density of β-adrenoceptors in cardiac membranes was
determined by (-) [125I]ICYP binding at six concentrations
ranging from 5 to 200 pmol/l as detailed elsewhere [29].
Non-specific binding of ICYP was defined as binding to
membranes which could not be displaced by a high con-
centration of the non-selective β-adrenoceptor antagonist
(±) CGP 12177 (1 µmol/l). Specific binding was defined
as total binding minus non-specific binding and usually
was about 70–80% at 50 pmol/l ICYP.
To determine the relative amounts of β1- and β2-adreno-
ceptors, membranes were incubated with increasing con-
centrations of the β2-adrenoceptor antagonist ICI
118,551 (10-10 – 10-4 M) and a constant concentration of
ICYP (100 pmol/l), and the specific binding assessed as
described above (using CGP12177). Binding curves were
analysed using the iterative curve fitting program Graph-
PadPrism (GraphPad Software, San Diego, CA, USA).
High Pressure Lquid Chromatography (HPLC)
Plasma norepinephrine content was assessed by high-
pressure liquid chromatography (HPLC) and electro-
chemical detection [30] using a commercial HPLC assay
(Chromsystems, Martinsried, Germany) based on the pro-
tocol by Goldstein [31] and by Hjemdahl et al. [32].
Briefly, catecholamines were adsorbed to aluminiumox-
ide (in prepacked columns; Chromsystems, Martinsried,
Germany) by shaking 1 ml plasma with 0.5 ml extraction
buffer (Tris-buffer) and aluminiumoxide for 10 min. As
internal standard 600 pg dihydroxybenzylamine were
added to the plasma sample. After 10 min, the probe was
washed twice and washing buffer was removed. Thereaf-
ter, the bound catecholamines and internal standard were
eluted using 120 µl elution buffer (Chromsystems, Mar-
tinsried, Germany) and filtration (at 700 g). 40 µl probe
volume were injected at a flow of 1 ml/min (HPLC
autosampler (GINA50) and pump (P580): Gynkotec,
Germering, Germany; mobile phase 5001; Chromsys-
tems, Martinsried, Germany) on a pre-equilibrated RP18
column (Chromsystems, Martinsried, Germany). The
HPLC system was controlled by the Chromeleon software
4.10 (Gynkotec, Germering, Germany). Catecholamines
were detected using an electrochemical detector (DEC-
ADE; flow cell: VT-03; Fa. ANTEC Comp., Leyden, Nether-
lands) (a working potential of 0.55 V yielded maximum
signals with lowest noise). An external calibration stand-
ard containing 5 ng/ml norepinephrine, 5 ng/ml dihy-
droxybenzylamine, 2.5 ng/ml epinephrine and 2.5 ng/ml
dopamine was also used for each experiment. Each sam-
ple was injected three times and the concentration was
determined as the mean of these three detections.
Histology
Tissue samples of the hearts were embedded in paraffin
and 5 µm sections of the hearts were stained with picrosir-
ius red according to standard protocols. Using fluores-
cence microscopy we identified the BMSC or their
remnants by Vybrand-DiI-red fluorescence and counted
the number of these BMSC (or remains) per visual field atJournal of Cardiothoracic Surgery 2006, 1:17 http://www.cardiothoracicsurgery.org/content/1/1/17
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200 x magnification. Moreover, we looked for signs of
inflammation, i.e. leukocyte/lymphocyte infiltration.
Mapping experiments
In order to investigate, whether BMSC injection might
produce inhomogeneities in the cardiac electrical activa-
tion pattern or autonomic areas, we submitted 4 hearts of
each group to epicardial mapping as previously described
[33]. Briefly, rabbits were anaesthetized by isoflurane, the
heart was excised and prepared according to the Langen-
dorff technique (constant pressure: 70 cm H2O, perfusion
with Tyrode solution (Na+ 161.02, K+ 5.36, Ca++ 1.8, Mg++
1.05, Cl- 147.86, HCO3- 23.8, PO42- 0.42 and glucose
11.1 mM, equilibrated with 95% O2 and 5% CO2 (pH =
7.4); the surface temperature of the heart was 37°C). The
hearts, which were beating at their spontaneous rate, were
connected to a 256 channel mapping system HAL4 (Ing.
Buero Peter Rutten, Hamburg, Germany, temporal resolu-
tion: 20 kHz per channel; amplitude resolution: 0.04 mV,
interchannel coupling <-60 decibel; bandwidth of the sys-
tem: 0.5 Hz – 100 kHz, data were not filtered) as
described previously [33]. 256 AgCl electrodes (1 mm
interelectrodes distance), which were attached to the heart
surface in an elastic manner, so that they could follow the
heart movements easily without dislocation. The four
plates were located at (a) the right wall (64 channels) (b)
the front wall (64 channels) (c) the left wall (64 channels)
and (d) the back wall (64 channels), so that both ventri-
cles were mapped with a total of 256 electrodes. Activa-
tion and repolarization time points at each electrode were
determined as t(dU/dtmin) or t(dU/dtmax), respectively
[33-35]. After automatic determination activation and
repolarization timepoints were verified (or corrected if
necessary) manually by the experimentator. Total activa-
tion time (TAT, [ms]) was calculated as the delay between
activation of the first and activation of the last electrode.
Standard deviation of activation times (SD(ACT)) was
used as a measure for local inhomogeneity. For each elec-
trode an activation-recovery-interval (ARI, reflecting epi-
cardial potential duration) was calculated.
Inhomogeneity of ARI was analyzed calculating standard
deviation of ARI at 256 electrodes (=ARI-dispersion).
Statistics
All continuous variables are presented as means ± S.E.M.
of n experiments. Experimental data to β-adrenoceptors
were fitted and analysed by computer-supported iterative
non-linear regression analysis using the GraphPadPrism
program (GraphPAD Software; San Diego, CA, USA). Sta-
tistical significance of differences was analysed by
unpaired two-tailed Student's t-test or, if appropriate, by
repeated measures ANOVA followed by t-test using Bon-
ferroni corrections for multiple comparisons. P < 0.05 was
considered to indicate a significant difference. The statisti-
cal evaluation was performed using SYSTAT program (Sys-
tat Inc., Evanston, IL, USA).
Chemicals
CGP12177, ICI118,551 were from Sigma (Taufkirchen,
Germany), (-) [125I]iodocyanopindolol (ICYP, specific
activity: 2200 Ci/mmol) (Perkin Elmer, Boston, MA,
USA), all other chemicals were of the purest commercially
available grade and obtained from Sigma.
Results
We found saturable ICYP binding in the membrane prep-
arations of all hearts. Unspecific binding was below 20%
of total binding at KD (example is given in fig. 1, upper
panel). Specific binding revealed different β-adrenoceptor
densities in left ventricle, septum and right ventricle with
lowest values in the right ventricle (fig. 1). Displacement
of ICYP by ICI 118,551 revealed a monophasic competi-
representative original ICYP binding data for one animal  (k042) from the control group given for left ventricle, sep- tum and right ventricle as total binding, unspecific binding and  specific binding Figure 1
representative original ICYP binding data for one animal 
(k042) from the control group given for left ventricle, sep-
tum and right ventricle as total binding, unspecific binding and 
specific binding.
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tion curve and a nearly undetectable β2-adrenoceptor
population (fig. 2).
Regarding the effects of disease and treatment, we found
significant down-regulation of β-adrenoceptor density in
untreated heart failure as compared to control (fig. 3).
This down-regulation was attenuated in BMSC-treated
animals (fig. 3). In sham operated animals with vehicle
injection, however, we found nearly the same down-regu-
lation as in failing hearts (fig. 4). The β-adrenoceptor
down-regulation in failing hearts was accentuated in sep-
tum and left ventricle (fig. 4). Most interestingly, in failing
hearts receiving BMSC transplantation the β-adrenoceptor
down-regulation was significantly attenuated in septum
and left ventricle as compared to sham operated failing
hearts (fig. 4). β-adrenoceptor density was nearly normal-
ized in septum of BMSC treated hearts and significantly
enhanced in left ventricle (as compared to sham operated
hearts), although still below the normal level (fig. 4). KD
was similar among all groups indicating unchanged affin-
ity (given in the legend to fig. 4).
Regarding catecholamine plasma concentrations HPLC
revealed clear and sharp peaks for norepinephrine, epine-
phrine and internal standard (fig. 5, panel A). In rabbits
with untreated heart failure we found significantly
enhanced norepinephrine and epinephrine levels (fig. 5,
panel B). The same holds true for rabbits suffering from
heart failure receiving sham-operation. In contrast, in rab-
bits with heart failure treated with BMSC transplantation
norepinephrine and epinephrine plasma levels were sig-
nificantly lower than in untreated or sham-operated rab-
bits (fig. 5, panel B).
In line with these findings, invasive in-vivo contractility
testing with Millar catheter revealed significantly
improved contractility in the BMSC treated animals (see
table 1). Thus, dP/dtmax and dP/dtmin under stimulation
with 1.5 µg/kg dopamine were largely decreased in failing
hearts and sham-operated failing hearts, while in failing
hearts which received BMSC transplantation this parame-
ter was significantly enhanced (see table 1). Pearson cor-
relation of β-adrenoceptor density and contractility (dP/
dtmax) revealed a significant correlation with R2 = 0.887
and p < 0.05.
By histological investigation of the hearts we found 2–3
intact cells/visual field (magnification 200 x) and some
remnants showing Vybrand DiI red fluorescence in BMSC
treated hearts in the vicinity of the injection marks, but
not in sham-operated or control hearts. However, these
few cells were found only in close neighbourhood of the
injection. In that area we also detected red fluorescent cell
detritus (fig. 6). We did not observe marked signs of an
inflammatory response such as leukocyte or lymphocyte
infiltration. However, in most normal, failing and treated
hearts a mild interstitial fibrosis was observed (fig. 6),
which was slightly more expressed in all failing hearts. At
the site of injection, we found a fibrotic scar (fig. 6). In all
animals suffering from heart failure body weight was
reduced and heart weight/body weight ratio was
increased. There were no significant differences among
the heart failure groups (table 1).
Regarding the subgroup of hearts which underwent map-
ping experiments, we found regularly beating hearts with
undisturbed propagation of the cardiac activation wave
front (fig. 7). The total activation time (TAT) was not dif-
Binding curves for control hearts, failing hearts and BMSC- treated failing hearts showing specific ICYP binding for left  ventricle Figure 3
Binding curves for control hearts, failing hearts and BMSC-
treated failing hearts showing specific ICYP binding for left 
ventricle.
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ferent among the groups as was the standard deviation of
the activation times at the 256 electrodes, which reflects
the inhomogeneity of the activation process (table 2; fig.
7). Thus, inhomogeneity of the activation process was not
enhanced by BMSC transplantation. The activation-recov-
ery intervals (ARI) were not changed by BMSC injection
versus sham-operated animals and the dispersion of ARI
also was not changed (table 2). We never observed spon-
taneously depolarizing areas in the ventricles or sustained
arrhythmia. The only finding was that in all failing heart
groups ARI was somewhat prolonged but without reach-
ing the level of significance.
Discussion
The results of our study clearly show -to the best of our
knowledge for the first time- an improvement and -as
assessed by β-adrenoceptor density- long-term improve-
ment of cardiac hemodynamic function by autologous
mesenchymal bone marrow stem cell transplantation in a
model of non-ischemic cardiomyopathy. Pathophysio-
logically the findings can be explained by the assumption
that doxorubicine-induced heart failure results in com-
pensatory catecholamine release (see fig. 5, panel B)
which in turn leads to β-adrenoceptor down-regulation
(see fig. 4). It is known that changes in β-adrenoceptor
density as a consequence of altered catecholamine levels
or β-blocker therapy in chronic heart failure mostly need
days or weeks to develop being related to the severity of
the disease [13,14,25-27,36]. If according to these studies
a therapy of heart failure is hemodynamically effective,
one has to assume that catecholamine release should
diminish and β-adrenoceptor density increased towards
normal values. This very point could be demonstrated
with the data in this paper showing a normalization of
both catecholamine levels and β-adrenoceptor density
together with improved contractility after BMSC trans-
plantation. Since it has been shown that normalization of
β-adrenoceptor density needs longer time periods with
improved hemodynamics [25,26], we assume that these
findings indicate a long-term improvement of cardiac
function by BMSC transplantation within the limitations
of this model. The positive and significant correlation
between  β-adrenoceptor density and contractility (R2 =
0.887, p < 0.05) supports the hypothesis on a relationship
between these two parameters. A point worth discussing is
the finding that the effects of BMSC transplantation are
more pronounced in the septum than in the free left ven-
tricular wall: the BMSC were injected in the free left ven-
tricular wall at 10 sites. Each injection produced a scar
(fig. 6) at the site of injection. In a tiny heart as the rabbit
heart 4 injections and the resulting scars will increase the
amount of fibrous tissue, which will not occur in the sep-
tum, since there are no injections made due to technical
reasons of the operation procedure. The scars and the
resulting change in the tissue composition in the left free
wall may overshadow in parts the effects of BMSC trans-
plantation on β-adrenoceptor density, which can be better
Table 1: Contractility given as dP/dtmax and dP/dtmin (mm Hg/s), body weight (g) and heart weight/body weight ratio (mg/g), given as 
MEANS ± SEM for each group. Significant differences versus normal animals are indicated by a * (p < 0.05), while significant changes 
versus sham-operated rabbits are indicated by a # (p < 0.05).
Series dP/dtmax dP/dtmin Body weight Heart weight/body weight
Control 2603 ± 281 -2102 ± 241 3633 ± 83 3.23 ± 0.10
Doxorubicine 1001 ± 126* -759 ± 86* 2587 ± 79* 4.12 ± 0.27*
Sham-operated 1290 ± 138* -860 ± 93* 2544 ± 84* 4.40 ± 0.20*
BMSC transplanted 2084 ± 151# -1616 ± 97# 2586 ± 79* 4.10 ± 0.20*
Quantitative data for β-adrenoceptor density in normal  hearts, failing hearts, sham-operated failing hearts and BMSC  transplanted failing hearts, given for left ventricle, septum and  right ventricle as MEANS ± SEM of n = 6 hearts in each  group Figure 4
Quantitative data for β-adrenoceptor density in normal 
hearts, failing hearts, sham-operated failing hearts and BMSC 
transplanted failing hearts, given for left ventricle, septum and 
right ventricle as MEANS ± SEM of n = 6 hearts in each 
group. Significant differences versus normal hearts are indi-
cated by a * (p < 0.05), while significant changes versus sham-
operated hearts are indicated by a # (p < 0.05). Correspond-
ing data for KD (septum, left ventricle (LV), right ventricle 
(RV)) were: 37 ± 3, 35 ± 4, 42 ± 3 (controls), 48 ± 6, 44 ± 6, 
48 ± 7 (doxorubicine), 47 ± 5, 46 ± 6, 48 ± 9 (sham operated 
hearts), 42 ± 9, 53 ± 8, 57 ± 14 (BMSC transplanted hearts); 
there were no significant differences between the KD values.
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upper panel (A): original plot showing electrochemical detection of norepinephrine, epinephrine and internal standard in rabbit  plasma Figure 5
upper panel (A): original plot showing electrochemical detection of norepinephrine, epinephrine and internal standard in rabbit 
plasma. lower panel (B): Quantitative data for plasma catecholamines in normal rabbits, in rabbits with doxorubicine-induced 
heart failure, rabbits suffering from heart failure after sham-operation, and BMSC transplanted rabbits with failing hearts, given 
as MEANS ± SEM of n = 6 rabbits in each group. Significant differences versus normal animals are indicated by a * (p < 0.05), 
while significant changes versus sham-operated rabbits are indicated by a # (p < 0.05).
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seen in the non-injected septum, if the hemodynamic sit-
uation is improved.
Regarding the relation between catecholamine levels and
β-adrenoceptor density and contractility, it is difficult to
say what is first. One may speculate, that the improved
hemodynamic situation should result in decreased cate-
cholamine levels, and that this will consequently lead to
attenuation of β-adrenoceptor down-regulation. How-
ever, it is also possible that BMSC-transplantation prima-
rily leads to enhanced β-adrenoceptor density or
attenuated down-regulation possibly by a paracrine effect,
which should then -analogous to beta-blocker treatment-
lead to an improved hemodynamic situation.
Numerous studies showed positive effects of BMSC trans-
plantation in ischemic heart disease or acute myocardial
infarction (e.g. [4,8,11]) either by direct infiltration or by
intracoronary stem cell injection (for a recent review see
[1]). It has been assumed that ischemia leads to expres-
sion of yet unknown homing factors attracting the stem
cells [37]. In non-ischemic cardiomyopathy it is unclear
whether such homing factors exist and, thus, we decided
to use direct myocardial infiltration technique for BMSC
application. The finding that we only found BMSC or their
remains in close vicinity of the injection speaks somewhat
against a predominant role of homing factors in this
model of non-ischemic cardiomyopathy although for a
final statement on this point (which was not the focus of
our study) experiments using e.g. intracoronary applica-
tion will be needed. Nevertheless, our data present the
first evidence for the efficacy of BMSC transplantation in
non-ischemic cardiomyopathy.
Regarding the underlying mechanisms of BMSC trans-
plantation there is an ongoing debate discussing factors
such as angiogenetic effects, transdifferentiation, cell
fusion and the release of paracrine factors [1,38]. First of
all, the lack of effect of medium injection (see sham-oper-
ated animals) demonstrates that it is not the trauma of
operation and injection; moreover, one could hypothe-
size that the BMSC injection might induce an inflamma-
tory response (although the cells are autologous).
However, we have no indication of a inflammatory lym-
phocyte or leukocyte infiltration of the ventricular myo-
cardium, which clearly is against the hypothesis of an
unspecific inflammation. Moreover, the sham operated
hearts were also injected with medium, but did neither
show inflammatory response nor therapeutic effect. A
Table 2: Electrophysiological findings of healthy, doxorubicine-treated and BMSC-treated rabbits in comparison to sham-operated 
animals. (Abbreviations: TAT: total activation time; ARI = activation-recovery interval; SD(ACT) : standard deviation of activation 
time; DISP: dispersion defined as standard deviation of activation-recovery interval). The differences among the groups were not 
significant.
Series TAT SD(ACT) ARI DISP
Control 17.3 ± 2.7 0.24 ± 0.04 128.4 ± 16.3 18.4 ± 2.4
Doxorubicine 18.1 ± 3.1 0.26 ± 0.04 147.1 ± 6.6 13.3 ± 1.0
Sham-operated 18.7 ± 4.3 0.28 ± 0.05 143 ± 7.4 14.1 ± 0.8
BMSC transplanted 19.5 ± 1.8 0.28 ± 0.03 141.6 ± 10.3 18.8 ± 3.5
Picrosirius red staining of the hearts of the control, doxoru- bicine, sham-operated, and BMSC-transplanted group Figure 6
Picrosirius red staining of the hearts of the control, doxoru-
bicine, sham-operated, and BMSC-transplanted group. As can 
be seen there is a mild interstitial fibrosis in all hearts, which 
is slightly more pronounced in the failing hearts. At the lower 
left, an injection site is shown, exhibiting the formation of a 
scar. At the lower right, red fluorescent cell detritus and 
some intact fluorescing cells are shown, which were found 
close to the injection site.
control doxorubicine
Doxorubicine + sham OP Doxorubicine + BMSC
Injection 
site
Remnants of the BMSC
80 µmJournal of Cardiothoracic Surgery 2006, 1:17 http://www.cardiothoracicsurgery.org/content/1/1/17
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myocardial transdifferentiation of BMSC, a hypothesis
broad forward by e.g. Tomita et al. [4] and others [5,39],
cannot be completely ruled out, but with 2–3 cells/visual
field at 200 x magnification and only in vicinity of the
injection) we have no indication for an amount of cells
undergoing transdifferentiation (or even being present as
they are) which would be large enough to explain the con-
tractile and hemodynamic improvement. Instead, one
could imagine that the injected cells release paracrine fac-
tors, yet unknown (or see above), which cause a response
of the surrounding myocardial tissue (including all types
of cells) being responsible for the process. Future studies
will have to be directed to the investigation of this hypoth-
esis and the identification of possible paracrine effects, if
existing.
Regarding the safety of BMSC transplantation the results
obtained with skeletal myoblasts indicate a possible
arrhythmogenic risk of cell therapy [40-42], so that a
deeper investigation seems to be necessary. Therefore, we
decided to investigate a subset of hearts by means of epi-
cardial potential mapping. We checked the number of epi-
cardial breakthroughpoints, looked for arrhythmogenic
foci and signs of inhomogeneity such as delayed activa-
tion or increased dispersion. None of these parameters
was different in BMSC transplanted hearts from failing
hearts without therapy. This does not completely rule out
arrhythmogeneic effects of this therapy in other (in partic-
ular later) phases of the therapy but these results show
that at least after 4 weeks no autonomic areas or non-
excitable zones (larger than 0.5 mm2) have been induced
by the therapy. Taking the low number of surviving cells
into account this seems reasonable. Thus, with all caution,
we have at present no indication of an arrhythmogenic
effect of autologous BMSC transplantation in non-
ischemic cardiomyopathy within the limitations of this
model.
Original isochrones (spacing 1 ms) of the epicardial activation of the hearts surface in an untreated failing heart (upper) and a  BMSC-treated (lower) failing heart (Y-electrode row 1 is caudal, while Y-electrode 8 is cranial; X-electrode location is indi- cated in the plot as right, front, left or back wall of the ventricles) Figure 7
Original isochrones (spacing 1 ms) of the epicardial activation of the hearts surface in an untreated failing heart (upper) and a 
BMSC-treated (lower) failing heart (Y-electrode row 1 is caudal, while Y-electrode 8 is cranial; X-electrode location is indi-
cated in the plot as right, front, left or back wall of the ventricles). Cumulative data for all hearts of this series are given in table 
2.Journal of Cardiothoracic Surgery 2006, 1:17 http://www.cardiothoracicsurgery.org/content/1/1/17
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Conclusion
The mechanism by which stem cell transplantation leads
to improvement of cardiac function is still uncertain and
further studies are on the way to elucidate this question.
The small number of surviving BMSC in our study is in
favour of the assumption of indirect effects such as e.g.
paracrine effects. Our data clearly show a long-term
improvement in cardiac function by autologous stem cell
therapy in non-ischemic cardiomyopathy, so that we con-
clude that this might be an interesting new therapeutic
approach to the treatment of non-ischemic cardiomyopa-
thy.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
Stefan Dhein had the idea of the study, performed data
analysis, statistics, graphics, and wrote the paper. Jens
Garbade did the surgery on the animals, isolated and char-
acterised the stem cells, and performed investigations of
contractility; Jan Fritz Gummert and Friedrich-Wilhelm
Mohr, both helped with the surgical techniques and
added important comments to the paper; Djazia Roua-
bah, Getu Abraham, and Fritz-Rupert Ungemach per-
formed the radioligand binding studies and analysed the
binding curves.
Katja Schneider performed anaesthesia of the animals and
the postoperative animal care. Cris Ullmann developed
the software for the pressure volume loops analysis and
analysed these data, Heike Aupperle performed all histo-
logical work on the hearts, and analysed the cell number
of surviving stem cells.
Acknowledgements
This study was generously supported by a grant from the Deutsche Stiftung 
für Herzforschung given to Stefan Dhein.
References
1. Dimmeler S, Zeiher AM, Schneider MD: Unchain my heart: the
scientific foundations of cardiac repair.  J Clin Invest 2005,
115:572-583.
2. Zimmet JM, Hare JM: Emerging role for bone marrow derived
mesenchymal stem cells in myocardial regenerative ther-
apy.  Basic Res Cardiol 2005, 100:471-481.
3. Ott HC, McCue J, Taylor DA: Cell-based cardiovascular repair –
the hurdles and the opportunities.  Basic Res Cardiol 2005,
100:504-517.
4. Tomita S, Li RK, Weisel RD, Mickle DA, Kim EF, Sakai T, Jia FQ:
Autologous tranplantation of bone marrow cells improves
damaged heart function.  Circulation 1999, 100:247-256.
5. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel
J, Mc Kay R, Nadal-Ginard B, Bodine DM, Leri N, Anversa P: Bone
marrow cells regenerate infarcted myocardium.  Nature 2001,
410:702-705.
6. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda
H, Silver M, Ma H, Kearney M, Isner JM, Asahara T: Therapeutic
potential of ex vivo expanded endothelial progenitor cells for
myocardial ischemia.  Circulation 2001, 103:634-637.
7. Strauer BE, Brehm M, Zeus T, Gattermann N, Hernandenz A, Sorg
RV, Kogler G, Wernert P: Myocardial regeneration after intra-
coronary transplanatation of human autogous stem cells fol-
lowing acute myocardial infarction.  Dtsch Med Wochenschr
2001, 126:932-938.
8. Strauer BE, Brehm M, Zeus T, Köstering M, Hernandez A, Sorg RV,
Kögler G, Wernet P: Repair of infarcted myocardium by autol-
ogous intracoronary mononuclear bone marrow cell trans-
plantation in humans.  Circulation 2002, 106:1913-1918.
9. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Brei-
denbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L,
Hertenstein B, Ganser A, Drexler H: Intracoronary autologous
bone-marrow cell transfer after myocardial infarction: the
BOOST randomised controlled clinical trial.  Lancet 2004,
364(9429):141-8.
10. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Silva GV,
Mesquita CT, Belem L, Vaughn WK, Rangel FO, Assad JA, Carvalho
AC, Branco RV, Rossi MI, Dohmann HJ, Willerson JT: Improved
exercise capacity and ischemia 6 and 12 months after
transendocardial  injection of autologous bone marrow
mononuclear cells for ischemic cardiomyopathy.  Circulation
2004, 110(11 Suppl 1):II213-8.
11. Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C,
Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S, Zeiher
AM:  Transplantation of progenitor cells and regeneration
enhancement in acute myocardial infarction: final one-year
results of the TOPCARE-AMI Trial.  J Am Coll Cardiol 2004,
44:1690-1699.
12. Böhm M, Diet F, Feiler G, Kemkes B, Kreuzer E, Weinhold C, Erd-
mann E: Subsensitivity of the failing human heart to isoprena-
line and milrinone is related to beta-adrenoceptor down-
regulation.  J Cardiovasc Pharmacol 1988, 12:726-732.
13. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS,
Lurie K, Billingham ME, Harrison DC, Stinson EB: Decreased cate-
cholamine sensitivity and beta-adrenergic-receptor density
in failing human hearts.  N Engl J Med 1982, 307:205-211.
14. Brodde OE, Michel MC, Zerkowski H-R: Signal transduction
mechanisms controlling cardiac contractility and their alter-
ations in chronic heart failure.  Cardiovasc Res 1995, 30:570-584.
15. Kiuchi K, Shannon RP, Komamura K, Cohen DJ, Bianchi C, Homcy CJ,
Vatner SF, Vatner DE: Myocardial beta-adrenergic receptor
function during the development of pacing-induced heart
failure.  J Clin Invest 1993, 91:907-914.
16. Engelhardt S, Böhm M, Erdmann E, Lohse MJ: Analysis of beta-
adrenergic receptor mRNA levels in human ventricular
biopsy specimens by quantitative polymerase chain reac-
tions: progressive reduction of beta 1-adrenergic receptor
mRNA in heart failure.  J Am Coll Cardiol 1996, 27:146-154.
17. Lohse MJ, Engelhardt S, Eschenhagen T: What is the role of β-
adrenergic signalling in heart failure?  Circ Res 2003, 93:896-906.
18. Lohse MJ: G-protein coupled receptor kinases and the heart.
Trends Cardiovasc Med 1995, 5:63-68.
19. Ungerer M, Böhm M, Elce JS, Erdmann E, Lohse MJ: Altered expres-
sion of beta-adrenergic receptor kinase and beta 1-adrener-
gic receptors in the failing human heart.  Circulation 1993,
87:454-463.
20. Ungerer M, Parruti G, Böhm M, Puzicha M, DeBlasi A, Erdmann E,
Lohse MJ: Expression of beta-arrestins and beta-adrenergic
receptor kinases in the failing human heart.  Circ Res 1994,
74:206-213.
21. Ping P, Anzai T, Gao M, Hammond HK: Adenylyl cyclase and G
protein receptor kinase expression during development of
heart failure.  Am J Physiol 1997, 273:H707-H717.
22. Rockman HA, Koch WJ, Lefkowitz RJ: Seven-transmembrane-
spanning receptors and heart function.  Nature 2002,
415:206-212.
23. Böhm M, Reiger B, Schwinger RHG, Erdmann E: cAMP concentra-
tions, cAMP dependent protein kinase activity, and phos-
pholamban in non-failing and failing myocardium.  Cardiovasc
Res 1994, 28:1713-1719.
24. Gilson N, Bouanani NEH, Corsin A, Crotazier B: Left ventricular
function and β-adrenoceptors in rabbit failing hearts.  Am J
Physiol 1990, 258:H634-H641.
25. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Lar-
rabee P, Bristow MR: Comparative hemodynamic, left ven-
tricular functional, and antiadrenergic effects of chronicPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Cardiothoracic Surgery 2006, 1:17 http://www.cardiothoracicsurgery.org/content/1/1/17
Page 11 of 11
(page number not for citation purposes)
treatment with metoprolol versus carvedilol in the failing
heart.  Circulation 1996, 94:2817-2825.
26. Sigmund M, Jakob H, Becker H, Hanrath P, Schumacher C, Eschenha-
gen T, Schmitz W, Scholz H, Steinfath M: Effects of metoprolol on
myocardial beta-adrenoceptors and Gi alpha-proteins in
patients with congestive heart failure.  Eur J Clin Pharmacol 1996,
51:127-132.
27. Harding SE, Brown LA, Wynne DG, Davies CH, Poole-Wilson PA:
Mechanisms of beta adrenoceptor desensitisation in the fail-
ing human heart.  Cardiovasc Res 1994, 28:1451-1460.
28. Schneider K: Anaesthesia of laboratory animals.  In Practical
Methods in cardiovascular Research Edited by: Dhein S, Mohr FW, Del-
mar M. Heidelberg: Springer Verlag; 2005:5-25. 
29. Brodde O-E, Vogelsang M, Broede A, Michel-Reher M, Beisenbusch-
Schäfer E, Hakim K, Zerkowski H-R: Diminished responsiveness
of Gs-coupled receptors in severely failing human hearts: no
difference in dilated versus ischemic cardiomyopathy.  J Car-
diovasc Pharmacol 1998, 31:585-594.
30. Bauersfeld W, Ratge D, Knoll E, Wisser H: Determination of cat-
echolamines in plasma by HPLC and amperometric detec-
tion. Comparison with a radioenzymatic method.  J Clin Chem
Clin Biochem 1986, 24:185-188.
31. Goldstein DS: Plasma catecholamines in clinical studies of car-
diovascular diseases.  Acta Physiol Scand 1984, 527(Suppl):39-41.
32. Hjemdahl P, Freyschuss U, Juhlin-Dahnfeld A, Linde B: Differenti-
ated sympathetic activation during mental stress evoked by
the stroop test.  Acta Physiol Scand 1984, 527(Suppl):25-29.
33. Dhein S, Müller A, Gerwin R, Klaus W: Comparative study on the
proarrhythmic effects of some antiarrhythmic agents.  Circu-
lation 1993, 87:617-630.
34. Durrer D, Van der Tweel LH: Spread of activation in the left
ventricular wall of the dog. Activation conditions at the epi-
cardial surface.  Am Heart J 1954, 47:192-203.
35. Millar CK, Kralios FA, Lux RL: Correlation between refractory
periods and activation recovery intervals from electro-
grams: effects of rate and adrenergic interventions.  Circulation
1985, 72:1372-1379.
36. Brodde OE, Michel MC: Adrenergic and muscarinic receptors
in the human heart.  Pharmacol Rev 1999, 51:651-690.
37. Vandervelde S, van Luyn MJ, Tio RA, Harmsen MC: Signalling fac-
tors in stem cell-mediated repair of infracted myocardium.
J Mol Cell Cardiol 2005, 39:363-376.
38. Dawn B, Bolli R: Adult bone marrow-derived cells: regenera-
tive potential, plasticity, and tissue commitment.  Basic Res
Cardiol 2005, 100:494-503.
39. Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW,
Entman ML, Michael LH, Hirschi KK, Goodell MA: Regeneration of
ischemic cardiac muscle and vascular endothelium by adult
stem cells.  J Clin Invest 2001, 107:1395-1402.
40. Menasché P, Hagege AA, Scorsin N, Pouzet B, Desnos N, Duboc D,
Schwartz Kl, Vilquin JT, Marolleau JP: Myoblast transplantation
for heart failure.  Lancet 2001, 357:279-280.
41. Menasche P, Hagege AA, Vilquin JT, Desnos M, Abergel E, Pouzet B,
Bel A, Sarateanu S, Scorsin M, Schwartz K, Bruneval P, Benbunan M,
Marolleau JP, Duboc D: Autologous skeletal myoblast trans-
plantation for severe postinfarction left ventricular dysfunc-
tion.  J Am Coll Cardiol 2003, 41:1078-1083.
42. Leobon B, Garcin I, Menasche P, Vilquin JT, Audinat E, Charpak S:
Myoblasts transplanted into rat infarcted myocardium are
functionally isolated from their host.  Proc Natl Acad Sci USA
2003, 100:7808-7811.